137 results
8-K
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
served as a member of the boards of directors of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology company, since 2019, including
8-K
EX-99.4
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
stock, based on their fair value on the date of the grant using the Black-Scholes model. Oruka measures restricted common stock awards using … of awards with service-based vesting conditions. Oruka accounts for forfeitures as they occur.
The Black-Scholes model uses inputs that are determined
8-K
EX-99.3
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards (“RSAs”) using the difference, if any … available for future grants.
Stock Option Valuation
The fair value of each stock option grant is estimated on the grant date using the Black-Scholes option
425
ORKA
Oruka Therapeutics Inc.
9 Aug 24
Business combination disclosure
8:35am
- IL - 17A/F Black box warning / significant safety concerns Highly safe; no AEs / SAEs of note Anti - IL - 12/23 Anti - IL - 17A Oral (various
425
ORKA
Oruka Therapeutics Inc.
6 Jun 24
Business combination disclosure
4:45pm
Anti - IL - 12/23 Anti - IL - 17A Anti - TNF Anti - IL - 17A/F Black box warning / significant safety concerns Mixed safety results; some AEs / SAEs
425
t8h1i4cc i67orv4
3 Apr 24
Business combination disclosure
7:33am
8-K
EX-99.2
de5y9493jpn5flzcx7di
3 Apr 24
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
7:31am